Patents generic

Stein, R. G. U.S. Patent 4,151,293 (1979), hfim. Abstr. 21= 56999d. Although this patent generically covered pyrethroid 9, the compound was not actually prepared. 

Expiry of patent generic free-for-all anyone free to make and market the compound, although processes may be protected by the original inventor company. 

An interesting scientific question raised by the new regulations was the point at which two drugs should be regarded as identical . The definition affects not only whether a novel drug could be patented as a new molecular entity but also whether an out-of-patent generic drug (see Section IV.D) could be approved on the basis of an AND A. 

Maikush structures are mainly used in patents, for protecting compounds related to an invention. The first generic claim, submitted by Markush, was granted in 1924 by the US Patent Office [87-90]. 

In contrast to canonical linear notations and connection tables (see Sections 2.3 and 2.4), fragment codes arc ambiguous. Several different structures could all possess an identical fragment code, because the code docs not describe how the fragments arc interconnected. Moreover, it is not always evident to the user whether all possible fi aginents of the stmetures ai e at all accessible. Thus, the fragments more or less characterise a class of molecules this is also important in generic structures that arise in chemical patents (sec Section 2.7.1)... 

Patent databases are therefore integrated databases because facts, text, tables, graphics, and structures are combined. In patents that include chemical aspects (mostly synthesis or processing), the chemical compounds are often represented by Markush structures (see Chapter 2, Section 2.7.1). These generic structures cover many compound families in a very compact maimer. A Markush structure has a core structure diagram with specific atoms and with variable parts (R-groups), which are defined in a text caption. The retrieval of chemical compounds from Markush structures is a complicated task that is not yet solved completely satisfactorily. 

CLAIMS UNITERM adds enhanced indexing to the chemical and chemically related patent records general terms to describe processes, properties, end products, etc specific compound terms (over 15,000) and chemical fragment terms to describe generic compounds. 

Other expansions of FDA s authority include the Dmg Price Competition and Patent Term Restoration Act of 1984, commonly known as the 1984 Amendments or the Waxman-Hatch Act, which was passed to attain quicker marketing of safe, effective, and less expensive generic dmgs and the Safe Medical Device Amendments of 1990, which was passed to correct perceived weaknesses in the implementation of the 1976 Device Amendments. Congress further expanded FDA authority over nutrition labeling and health and nutrient content claims on food labels with the Nutrition Labeling and Education Act of 1990. 

Acetylsalicylic acid [50-78-2] (i9-acetyoxyben2oic acid) was first synthesized in 1853 by reaction of acetyl chloride with sodium saUcylate. As a dmg, acetylsahcyhc acid was introduced in Germany in 1899 and into the United States in 1900. The first U.S. patent (35) for the manufacture of acetylsaUcyhc acid expired in 1917. Aspirin is a registered trademark of Bayer in many nations, but in the United States and the United Kingdom, aspirin is accepted as the generic name for acetylsahcyhc acid (36). 

The sales of oral diuretics are declining, and are forecast to continue their decline in constant dollars during the 1990s (119,120). Several possible explanations can be offered for these trends. The patents of market leaders are expiring, lea ding to the introduction of generic brands at ca 40% below the cost of the branded market leaders physicians are switching to newer treatments for hypertension, eg, calcium channel blockers and... 

As patents expire, exclusivity of producing a trade-nemed product will pass and competitive-versions of the basic drug will be marketed under generic names (or other new trade nemes) by new manufacturers. It has been estimated that 40% of the drugs on the market in 1990 will be generic drugs. 

Table 10.8 outlines the quality requirements of the basis, or primary, metal for the three generic types of anode. These are the qualities required even when sequestering is also adopted. It will be seen that two grades are listed in the case of aluminium. This is because certain patented formulations permit the lower (99- 8%) grade material providing that the iron and silicon are within the limit given. 

We should not minimize the effects that electronic searching of patents has had on the business of research. In 1990, CAS introduced MARPAT, which is a database of Markush (generic) structures found in patent documents [1]. This database provided a valuable tool for patent searching in a more comprehensive way than had been available previously. In 1995, CAS launched SciFinder, which provided access to the patent literature for chemists on their desktops. Using the SciFinder interface, one may search for research topics, authors, companies, or structures/reactions. From a practical viewpoint, SciFinder did more to enhance the searching capabilities of the medicinal chemist than any other tool. Even today, SciFinder continues to provide a first pass through the patent literature when chemists want to include patents in their searching. Indeed, when a search is performed, patent references are included in the answer set. Only very recently have there been additional tools to search the patent literature that have found widespread use. 

It comprises several wafers with different functional elements such as micro heat exchanger, mini fixed-bed catalyst chambers, manifolding structures and other components not disclosed. The flow partitioning was performed in a hierachic manner. A patent gives deeper insight into the generic construction architecture of the micro-reaction system. The wafers were bonded to a stack and equipped with fluid connections [137]. 

The topic of generic bioequivalence pertains to the relative bioavailability of different versions of the same drug product, all of which may be available in the marketplace at the same time. Thus, if we continue our consideration of the example introduced in the previous section of this chapter, let us suppose that the innovator did obtain approval to market F3. Initially F3 was the only product available in the marketplace. However, when the relevant patents held by the innovator have expired, other pharmaceutical... 

---